<DOC>
	<DOCNO>NCT00466635</DOCNO>
	<brief_summary>Approximately 65 patient enter study take place North America . The aim study evaluate safety , efficacy absorption investigational drug patient C. difficile-associated diarrhea ( CDAD ) . All study relate care provide include doctor visit , physical exam , laboratory test study medication . Total length participation 6 week .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Effectiveness Absorption Exodifâ„¢ Tablets Clostridium Difficile-associated Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Enterocolitis</mesh_term>
	<mesh_term>Enterocolitis , Pseudomembranous</mesh_term>
	<criteria>The presence CDAD time enrollment Negative serum pregnancy test ( HCG ) woman childbearing potential . Any contraindication oral / enteral therapy include fulminant C. difficile disease . Any acutely lifethreatening medical condition . Acute chronic diarrhea cause .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Clostridium difficile Disease</keyword>
	<keyword>Infectious diarrhea</keyword>
	<keyword>C. difficile</keyword>
	<keyword>CDAD</keyword>
	<keyword>Clostridium difficile-associated diarrhea</keyword>
	<keyword>Clostridium difficile diarrhea</keyword>
	<keyword>Antibiotic-Associated Colitis</keyword>
	<keyword>Clostridium Enterocolitis</keyword>
	<keyword>Antibiotic-Associated Diarrhea</keyword>
	<keyword>Pseudomembranous Colitis</keyword>
	<keyword>Clostridium difficile</keyword>
</DOC>